<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:atom="http://www.w3.org/2005/Atom"
xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
>
<channel>
	<title>ThaiPR.NET</title>
	<atom:link href="https://www.thaipr.net/location/baar-switzerland/feed" rel="self" type="application/rss+xml" />
	<link>https://www.thaipr.net/location/baar-switzerland</link>
	<description>Press Release Distribution Center of Thailand</description>
	<lastBuildDate>Thu, 23 Apr 2026 17:31:43 +0700</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.1.1</generator>
	<item>
		<title><![CDATA[Orpha Labs AG Initiates Compassionate Use Program for ORL-101 in Leukocyte Adhesion Deficiency Type II (LAD-II)]]></title>
		<link>https://www.thaipr.net/en/health_en/3026583</link>
		<dc:creator><![CDATA[thaipr.net]]></dc:creator>
		<pubDate>Mon, 08 Feb 2021 14:20:12 +0700</pubDate>
				<category>health_en</category>
		<guid isPermaLink="false">https://www.thaipr.net/en/health_en/3026583</guid>

					<description><![CDATA[<p>First Patient to Receive ORL-101 in Israel This Week Orpha Labs AG today announced its compassionate use program to make ORL&#8211;101 available to physicians providing care for Leukocyte Adhesion Deficiency Type II (LAD-II) patients. ORL-101 is a novel formulation of an ultra-pure L-fucose currently in development for the treatment of LAD II patients. The Israeli [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.thaipr.net/en/health_en/3026583">Orpha Labs AG Initiates Compassionate Use Program for ORL-101 in Leukocyte Adhesion Deficiency Type II (LAD-II)</a> appeared first on <a rel="nofollow" href="https://www.thaipr.net">ThaiPR.NET</a>.</p>
]]></description>
									</item>
	</channel>
</rss>
